These innovative molecules represent a significant advancement in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://janagpkl337017.blog-kids.com/39526524/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide